Page 8 of 10 – SEC Filing
CUSIP No. 09069N108 (Common Stock)
Explanatory Note: This Amendment No. 4 (this Amendment) to the Schedule 13D relating
to BioScrip, Inc., a Delaware corporation (the Issuer), filed by the Filers (as defined below) with the U.S. Securities and Exchange Commission (the Commission) on March 19, 2015 (the Initial 13D), as amended
and supplemented by Amendment No. 1 to the Initial 13D filed on August 27, 2015, Amendment No. 2 to the Initial 13D filed on April 5, 2016, and Amendment No. 3 to the Initial 13D filed on June 22, 2016, amends and
supplements certain of the items set forth therein.
As used in this Amendment, the term Filers collectively refers to:
| Coliseum Capital Management, LLC, a Delaware limited liability company (CCM); |
| Coliseum Capital, LLC, a Delaware limited liability company (CC); |
| Coliseum Capital Partners, L.P., a Delaware limited partnership (CCP); |
| Coliseum Capital Partners II, L.P., a Delaware limited partnership (CCP2); |
| Adam Gray (Gray); and |
| Christopher Shackelton, a director of the Issuer (Shackelton). |
Item 5. Interest in
Securities of the Issuer.
Item 5 is amended and supplemented as follows:
The information relating to the beneficial ownership of shares of common stock, $0.0001 par value per share (the Common Shares) of BioScrip, Inc.
(the Issuer) by each of the Filers set forth in Rows 7 through 13 of the cover pages hereto is incorporated herein by reference. The percentages set forth in Row 13 for all cover pages filed herewith are calculated based upon
127,475,226 Common Shares outstanding as of August 7, 2017, as reported in the Issuers Form 10-Q for the quarterly period ended June 30, 2017, filed with the Commission on August 8, 2017.
The Filers effected the following transactions in the Common Shares in open market transactions on the dates indicated, and such transactions are the
only transactions in the Common Shares by the Filers in the sixty days preceding the filing of this Amendment.
|
| Purchase or Sale | Date | Number of Shares | Weighted Average Price Per Share | ||||||||||||
| CCP | Sale | 08/15/17 | 134,889 | $ | 3.15 | |||||||||||
| CCP2 | Sale | 08/15/17 | 32,082 | $ | 3.15 | |||||||||||
| Separate Account | Sale | 08/15/17 | 49,329 | $ | 3.15 | |||||||||||
| CCP | Sale | 08/16/17 | 72,184 | $ | 3.11 | |||||||||||
| CCP2 | Sale | 08/16/17 | 17,155 | $ | 3.11 | |||||||||||
| Separate Account | Sale | 08/16/17 | 26,363 | $ | 3.11 | |||||||||||
| CCP | Sale | 08/17/17 | 345,751 | $ | 3.05 | |||||||||||
| CCP2 | Sale | 08/17/17 | 82,169 | $ | 3.05 | |||||||||||
| Separate Account | Sale | 08/17/17 | 126,556 | $ | 3.05 | |||||||||||
Except as set forth in Item 6 hereof, no other person has the right to receive or the power to direct the receipt of dividends
from, or the proceeds from the sale of, the Common Shares, the Series A Convertible Preferred Stock, par value $0.0001 per share (the Series A Preferred Shares), the Series C Convertible Preferred Stock, par value $0.0001 per share (the
Series C Preferred Shares and, together with the Series A Preferred Shares, the Preferred Shares) the Class A warrants to purchase Common Shares at a price of $5.17 per share (the Class A Warrants) or
the Class B warrants to purchase Common Shares at a price of $6.45 per share (the Class B Warrants and , together with the Class A Warrants, the Warrants) reported herein.
Page 8 of 10
